Sandip Patel
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (34)
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.
Year:
2025
A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.
Year:
2025
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.
Year:
2025
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.
Year:
2025
Fusion detection stratified by cancer indications with and without FDA-approved targeted therapy. A, Fusions detected in FDA-approved and non–FDA-approved indications aggregated across fusion drivers (see Supplementary Table S1). B, Percent of driver fusions detected by analyte for FDA-approved and non–FDA-approved indications. C, Counts of fusions detected in FDA-approved and non–FDA-approved indications by fusion driver.
Year:
2025
Emerging fusion detection by analyte and cancer type. A, Pan-cancer fusion prevalence by emerging fusion driver. B, For each emerging fusion driver, percent of fusions detected by analyte: RNA-only, DNA-only, or detected by both RNA and DNA (all patients received both RNA-NGS and DNA-NGS testing). C, Combined emerging fusion prevalence by cancer type for the two emerging driver fusions. D, For each cancer type, percent of combined emerging driver fusions detected by analyte: RNA-only, DNA-only, or detected by both RNA and DNA. For C and D , cancer types with
Year:
2025
Gene expression and RNA fusion partners in FGFR2 , FGFR3 , and NRG1 fusions. A–C, Gene expression TPM by cancer type in fusion-positive and fusion-negative patients for ( A ) NRG1 , ( B ) FGFR3 , and ( C ) FGFR2 . All FDA-approved indications and non–FDA-approved indications are separated by the gray lines. D–F, Fusion driver partners identified by RNA stratified by cancer type for the following fusions: ( D ) NRG1 , ( E ) FGFR3 , and ( F ) FGFR2 . All FDA-approved indications and the top three non–FDA-approved indications by fusion count are shown, with the remaining non–FDA-approved indications grouped into the “other” cancer type category. Fusion partners that only appear in a single patient (or only in two patients in the case of FGFR2 ) are grouped into the “other” partner category. HNSCC, head and neck squamous cell carcinoma.
Year:
2025
Fusion detection by analyte and cancer type. A, Pan-cancer fusion prevalence by fusion driver. B, For each fusion driver, percent of fusions detected by analyte: RNA-only, DNA-only, or detected by both RNA and DNA. C, Combined fusion prevalence by cancer type for all nine driver fusions. D, For each cancer type, percent of combined driver fusions detected by analyte: RNA-only, DNA-only, or detected by both RNA and DNA. For C and D , cancer types with FGFR2 and ROS1 , NRG1 and NTRK3 , NRG1 and RET , and RET and ROS1 .
Year:
2025
Gene fusions are a class of important oncogenic drivers, with many matched FDA-approved targeted therapies across multiple solid tumors. However, the prevalence of fusions varies considerably by cancer type and assay. Fusion detection is technically challenging, and studies have shown that RNA-based next-generation sequencing (NGS) can improve fusion detection rates when used in conjunction with DNA-based NGS. In this study, we performed a retrospective pan-cancer analysis of 67,278 patients receiving both RNA- and DNA-NGS in 43 distinct solid-tumor cancer types, including non–small cell lung cancer (18.6%), colorectal cancer (18.2%), and breast cancer (13.1%). In this cohort, 1,497 patients (2.2%) had at least one of nine fusions detected—each having an FDA-approved matched therapy in at least one indication. A total of 316 patients (21.1%) had a fusion detected ( RET or NTRK1/2/3 ) with matched targeted therapy approved in all cancer indications. Concurrent RNA- and DNA-NGS increased the detection of driver gene fusions by 21% compared with DNA-NGS alone. Gene fusions were observed in a range of cancers beyond their approved cancer indications: of 1,501 fusions detected, 29% ( n = 437) were detected outside of an FDA-approved indication. Finally, emerging fusion drivers with targets in drug development were found in an additional 218 patients, with combined RNA- and DNA-NGS increasing detection of these variants by 127%. Our findings support combined RNA-NGS and DNA-NGS to maximize detection of clinically actionable fusions with FDA-approved matched therapies and potentially actionable fusions in non–FDA-approved indications or those matched to therapies in clinical development. Significance: This large, real-world pan-cancer study demonstrates that concurrent RNA- and DNA-based NGS significantly improves the detection of clinically actionable gene fusions compared with DNA-NGS alone. Our findings highlight the critical value of integrating RNA-NGS into routine molecular profiling to optimize the detection of driver gene fusions. Doing so may expand the population of patients eligible for matched targeted therapies or clinical trials, particularly in cancers with limited treatment options.
Year:
2025
Description of fusions and indications assessed in this study. The grid of fusion drivers (rows) and major indications (columns) highlights the variability in FDA-approved therapies. Given pan-cancer approvals, all listed indications have “indication-matched” approved therapies targeting RET and NTRK1/2/3 . By contrast, BRAF and EGFR are considered emerging fusion targets as there are no FDA-approved therapies specifically targeting these in any indication. The remainder of assessed fusion drivers have FDA-approved targeted therapies in certain indications but not others (see also Supplementary Table S1).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (44)
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Neal Akhave
Assistant Professor
The University of Texas MD Anderson Cancer Center
Christine Bestvina
Assistant Professor
University of Chicago Medicine
Marina Garassino
Prof
Università degli Studi di Torino
Matthew Zibelman
Assistant Professor
Fox Chase Cancer Center
Jacobi Hines
Assistant Professor
Northwestern Medicine
Qi Wang
The University of Texas MD Anderson Cancer Center
Mizuki Nishino
King’s College London
Petros Christopoulos
-
Amy L Cummings
UCLA School of Medicine
Talia Golan
-
Elad Sharon
Associate Professor
Harvard University
Young Kwang Chae
Northwestern University Feinberg School of Medicine
Ezra Cohen
Professor of Medicine
Moores Cancer Center, UC San Diego Health
Giorgio V Scagliotti
Chair
University of Turin
james hicks
H Lee Moffitt Cancer Center and Research Institute
Jennifer Scalici
Professor
Winship Cancer Institute of Emory University
Mingjia Li
Assistant Professor
Ohio State University
Mark Stein
Associate Professor
Columbia University Irving Medical Center
Collin Blakely
Assistant Professor
UCSF Medical Center
Matthias Scheffler
University Hospital Bonn
John V. Heymach
The University of Texas MD Anderson Cancer Center
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Leonard Appleman
Associate Professor
University of Pittsburgh
Ben Ho Park
Vanderbilt University Medical Center
Wolfram Samlowski
University of Nevada
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
David S. Hong
The University of Texas MD Anderson Cancer Center
Heather Wakelee
Professor
Stanford University
Razelle Kurzrock
-
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Megan Othus
Fred Hutchinson Cancer Research Center
Ying Ni
Assistant Professor
Case Western Reserve University
Catherine Shu
Columbia University Irving Medical Center
Ferdinandos Skoulidis
The University of Texas MD Anderson Cancer Center
Albrecht Stenzinger
-
Jayanthi Lea
Associate Professor
University of Texas Southwestern Medical School
Marcelo Negrao
Assistant Professor
The University of Texas MD Anderson Cancer Center
Don L. Gibbons
The University of Texas MD Anderson Cancer Center
Dwight H. Owen
Ohio State University
Timothy Yap
The University of Texas MD Anderson Cancer Center
Jason J. Luke
-
Make your next move.
Prepare your application
Review drafts before you send them.